2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.06G.16 Pleural Fluid EGFR Mutation Testing in 10 Patients with Advanced Lung Adenocarcinoma with Pleural Effusion

EP.06G.16 Pleural Fluid EGFR Mutation Testing in 10 Patients with Advanced Lung Adenocarcinoma with Pleural Effusion

Pdf Summary

The study focuses on testing for EGFR mutations in pleural fluid samples from patients with advanced lung adenocarcinoma and malignant pleural effusion (MPE). Conducted at Incheon St. Mary's Hospital, the researchers collected pleural fluid from 11 patients and analyzed it for EGFR mutations, comparing results with tissue and serum samples.<br /><br />In the results, 10 of the 11 patients were diagnosed with lung cancer. Among them, 8 underwent comprehensive EGFR mutation testing across tissue, serum, and pleural fluid samples. Of these, 4 patients tested positive for EGFR mutations in all sample types, with two exhibiting the Exon 19 deletion mutation and two having the L858R mutation. Additionally, pleural fluid samples consistently contained higher levels of circulating free DNA (cfDNA) than serum samples. One notable case involved a patient with the L858R mutation and progressive MPE, who tested negative for the T790M resistance mutation in serum but positive in pleural fluid.<br /><br />The study concludes that pleural fluid EGFR mutation testing is both efficient and reliable, offering higher tumor-derived DNA concentrations and easy sample accessibility. This method is particularly advantageous in detecting resistance mutations such as T790M, crucial for guiding treatment decisions in advanced lung cancer cases. The researchers encourage future studies to expand the sample size and explore prospective methodologies to substantiate these initial findings.

Asset Subtitle

Yu Jin Hong

Meta Tag

Speaker Yu Jin Hong

Topic Pathology and Biomarkers

Keywords

EGFR mutations

pleural fluid

lung adenocarcinoma

malignant pleural effusion

cfDNA

Exon 19 deletion

L858R mutation

T790M resistance mutation

tumor-derived DNA

advanced lung cancer